Document:

Exhibit

Exhibit 10.5
Lockheed Martin Corporation
6801 Rockledge Drive Bethesda, MD 20817
Telephone 301 897 6000

March 12, 2020

James D. Taiclet, Jr.

Dear Jim, 

On behalf of the Board of Directors, we are pleased to offer you the position of President and Chief Executive Officer located in Bethesda, MD. 

Your initial base salary will be $1,700,000 per year.  As you know, the salary of the CEO is reviewed annually by the Board of Directors.  You will be paid on a weekly basis, with one week in arrears. 

Your annual incentive target opportunity under the company’s Management Incentive Compensation Plan (MICP) will be 175% of your base salary for 2020, which will be pro-rated based on your start date.  Payouts are generally made in March following the performance year and range from 0-200% of your target opportunity based on performance results relative to pre-established goals. All payouts are subject to review and approval by the Board of Directors. You must be employed through the end of the year to receive a payout.

You will be nominated for an annual long-term incentive (LTI) award of $14,000,000 for 2020. The award will be allocated 50% in Performance Stock Units (PSUs), 30% in Restricted Stock Units (RSUs) and 20% in the cash-based Long-Term Incentive Performance award (LTIP).  The RSUs if granted will cliff vest 100% three years from the date of grant while the vesting of the PSUs and LTIP if granted will vest in February 2023 based on company performance at the end of the three-year vesting period (2020-2022) relative to the three-year performance goals that were set in February 2020. Additionally, you will be nominated to receive a one-time special LTI grant of RSUs to offset forfeiture of unvested incentive awards from your current employer, to be determined following your retirement. These awards are subject to review and approval by the Corporation’s Management Development and Compensation Committee.  

Since this position will require you to relocate, you will also be entitled to relocation benefits under our applicable relocation policy, a copy of which will be provided to you.  You will also be entitled to participate in the company’s savings plan with a 401(k) feature, as well as a non-qualified supplemental savings plan, and other health and welfare benefits available to salaried employees.  Lockheed Martin reserves the right to amend or to terminate its benefits plans at any time.  

While we are confident that we will have a satisfactory employment relationship, Lockheed Martin is an at-will employer and you will serve at the discretion of the Board of Directors.  This means that either you or Lockheed Martin may end the employment relationship for any or no reason and without advance notice.  If this offer is acceptable, please sign below.  

We are very pleased to make this offer and look forward to a bright future together.

Sincerely, 

/s/ Daniel F. Akerson

Daniel F. Akerson
Offer Acceptance:

/s/ James D. Taiclet, Jr.
_____________________________
James D. Taiclet, Jr.Exhibit 4.4

  

   

  

  
    

    

    

    

    	 	 	 
            MorphoSys AG

            Semmelweisstraße 7

            82152 Planegg

            Germany

             

            

          
	 	 	Telefon:	+49 (0)89 899 27-0
	 	RSUP 2020 (US Inc.)	Fax:	+49 (0)89 899 27-222
	 	 	
            Email:

          	info@morphosys.com
	 	 	Internet:   

            	www.morphosys.com
	 	 	
            

              MorphoSys US Inc.

            470 Atlantic Avenue

            Boston, MA 02210

            USA 

    

    

    

    

    Restricted Stock Unit Program 2020 (US Inc.) for senior managers and employees (including directors and officers) of MorphoSys US Inc.

    

    

    Introduced by decision of the Vorstand of MorphoSys AG, with the consent of the Supervisory Board of MorphoSys AG, as of 1 April 2020

    

    

    

    

    	
            - Terms and Conditions -

          

    

    

    

    

    MorphoSys AG

    Semmelweisstraße 7

    82152 Planegg

    Germany

    

    

    MorphoSys US Inc.

    470 Atlantic Avenue

    Boston, MA 02210

    USA

    

    

    

    

    

    

    

    

    

    

    	
            Vorstand

            Dr. Jean-Paul Kress (Vorsitzender),

            Jens Holstein, Dr. Malte Peters

            Vorsitzender des Aufsichtsrats

            Dr. Marc Cluzel

             

          	
            Bankverbindung

            Commerzbank

            BLZ: 700 800 00

            Kto.: 0349775600

            IBAN: DE73 7008 0000 0349 7756 00

            SWIFT (BIC): DRESDEFF700

          	
            St.-Nr.

            9143/101/21259

            USt-ID. Nr.

            DE 15506 9821

             

             

          	
            Sitz der Gesellschaft

            Planegg, Landkreis München

            Handelsregister

            AG München HRB 121023

             

             

          

    

    

    
      
        

    

    
    

    

    TABLE OF CONTENT

    	
            TABLE OF CONTENT

          	
            2

          
	
            DEFINITIONS

          	
            3

          
	
            RECITALS

          	
            4

          
	
            § 1

          	
            ELIGIBILITY

          	
            5

          
	
            § 2

          	
            PLAN VOLUME AND GRANT OF RSUs

          	
            5

          
	
            § 3

          	
            WAITING PERIOD, ANNUAL CYCLE AND VESTING

          	
            6

          
	
            § 4

          	
            KEY PERFORMANCE INDICATORS

          	
            7

          
	
            § 5

          	
            CONSEQUENCES OF A TERMINATION OF EMPLOYMENT

          	
            10

          
	
            § 6

          	
            CASH PAYMENT CLAIM RESULTING FROM RSUs AND SETTLEMENT OF RSUs

          	
            11

          
	
            § 7

          	
            TRANSFERABILlTY

          	
            14

          
	
            § 8

          	
            CHANGE OF CONTROL

          	
            14

          
	
            § 9

          	
            ADJUSTMENT IN CASE OF SPECIFIC CAPITAL AND OTHER STRUCTURAL MEASURES

          	
            16

          
	
            § 10

          	
            EXTRAORDINARY DEVELOPMENTS

          	
            17

          
	
            § 11

          	
            INSIDER TRADING AND BLACK-OUT PERIODS

          	
            17

          
	
            § 12

          	
            LIMITATION OF LIABILITY

          	
            18

          
	
            § 13

          	
            TAXES, SOCIAL SECURITY AND COSTS

          	
            19

          
	
            § 14

          	
            FORM REQUIREMENTS

          	
            20

          
	
            § 15

          	
            PROCESSING OF PERSONAL DATA

          	
            21

          
	
            § 16

          	
            GOVERNING LAW AND JURISDICTION

          	
            21

          
	
            § 17

          	
            FINAL PROVISIONS

          	
            21

          

    

    

    
      Page 2/26

      
        

    

    DEFINITIONS

    

    

    	
            Adjustment Event

          	
            16

          	 	
            Insider Trading Rules

          	
            17

          
	
            Annual Cycle

          	
            7

          	 	
            KPI

          	
            7

          
	
            Annual Cycles

          	
            7

          	 	
            KPI Achievement Rate

          	
            8

          
	
            Authorized Capital 2019-I

          	
            4

          	 	
            KPIs

          	
            7

          
	
            Award Agreement

          	
            5

          	 	
            Leaver

          	
            11

          
	
            Award Amount

          	
            5

          	 	
            MorphoSys

          	
            4

          
	
            Award Date

          	
            6

          	 	
            MorphoSys US

          	
            4

          
	
            Award Period

          	
            6

          	 	
            Notices

          	
            20

          
	
            Black-Out Periods

          	
            18

          	 	
            Officers

          	
            4

          
	
            Board of Directors

          	
            5

          	 	
            Overall KPI Achievement Rate

          	
            9

          
	
            Cap

          	
            9

          	 	
            Participant

          	
            5

          
	
            Capital Increase Resolution Date

          	
            12

          	 	
            Revenue KPI

          	
            8

          
	
            Cash Payment Claim

          	
            11

          	 	
            Revenue KPI Achievement Rate

          	
            9

          
	
            Cash Settlement

          	
            12

          	 	
            Revenue Performance

          	
            8

          
	
            Cash Settlement Date

          	
            12

          	 	
            RSU

          	
            4

          
	
            Change of Control

          	
            14

          	 	
            RSUP 2020 (US Inc.)

          	
            4

          
	
            Company

          	
            4

          	 	
            RSUP Resolution

          	
            4

          
	
            Conversion

          	
            5

          	 	
            RSUP Terms & Conditions

          	
            4

          
	
            Data Subjects

          	
            24

          	 	
            RSUs

          	
            4

          
	
            Directors

          	
            4

          	 	
            Share Price KPI

          	
            8

          
	
            EBIT KPI

          	
            7

          	 	
            Share Price KPI Achievement Rate

          	
            9

          
	
            EBIT KPI Achievement Rate

          	
            9

          	 	
            Share Price Performance

          	
            8

          
	
            EBIT Performance

          	
            8

          	 	
            Share Settlement

          	
            12

          
	
            Employees

          	
            4

          	 	
            Share Settlement Date

          	
            12

          
	
            Euro Award Amount

          	
            5

          	 	
            Shares

          	
            4

          
	
            External Service Provider

          	
            25

          	 	
            Termination Date

          	
            11

          
	
            Extraordinary Events or Developments

          	
            17

          	 	
            Transaction

          	
            17

          
	
            GDPR

          	
            24

          	 	
            Vested RSUs

          	
            7

          
	
            Hurdle

          	
            9

          	 	
            Waiting Period

          	
            6

          
	
            Initial Number of RSUs

          	
            6

          	 	
            Waiting Period Expiration Date

          	
            6

          

    

    

    
      Page 3/26

      
        

    

    RECITALS

    An attractive and competitive remuneration program is essential for the recruitment and long-term commitment of highly qualified employees.

    In JuIy 2018, MorphoSys AG (“MorphoSys” or
      the “Company”) has founded a 100% subsidiary in the USA, MorphoSys US Inc. (“MorphoSys US”). As part of MorphoSys’ intention to develop a strong presence in the USA and recruit and retain highly qualified employees at MorphoSys US, a share-based employee participation program
      is required which takes into account US standards and expectations.

    Therefore, MorphoSys intends to implement a “Restricted Stock Unit Program” (the “RSUP 2020 (US Inc.)”) as a long-term remuneration component for senior managers and employees of MorphoSys US (including directors of MorphoSys US (“Directors”) and officers of MorphoSys US (“Officers”)) (senior managers and
      employees of MorphoSys US, including Directors and Officers hereinafter collectively the “Employees”). Under the RSUP 2020 (US Inc.), the
      Company shall be allowed to grant so-called “Restricted Stock Units” (“RSUs” and each a “RSU”) to the Employees, which – if certain requirements are met – grant the Employees a claim against the Company for a cash payment, the amount of which depends, amongst others, on
      the stock exchange price of the shares of the Company (the “Shares”). However, the RSUP 2020 (US Inc.) shall include a substitution right of
      the Company, permitting it to fulfil the payment claims of the Employees resulting from the RSUs by delivering Shares instead of cash.

    With resolution dated 22 May 2019, the Company’s General Meeting (Hauptversammlung)
      has authorized the Management Board (Vorstand), with the consent of the Supervisory Board (Aufsichtsrat), until 30 April 2024 (including) to increase the Company’s registered share capital by up to € 159,197.00 against cash contributions and/or contributions in kind once or several times by issuing up to
      159,197 new no-par value bearer Shares (auf den Inhaber lautende Stückaktien) (“Authorized Capital 2019-I”). The Authorized Capital 2019‐I only serves the purpose of delivering Shares of the Company against the contribution of cash payment claims resulting from RSUs, in order to settle RSUs that
      were granted to Employees.

    
      Page 4/26

      
        

    

    The present terms and conditions (the “RSUP Terms
        & Conditions”) establish the rules pursuant to which the RSUs under the RSUP 2020 (US Inc.) can be granted and settled.

    § 1

      ELIGIBILITY

    
      
        	

              	1.1	
                RSUs can be granted to Employees (each a “Participant”).

              

      

    

    
      
        	

              	1.2	
                Persons who, at the same time to being an Employee, are members of the Company’s Management Board, or are an employee of the Company, are not eligible to participate in the RSUP
                  2020 (US Inc.).

              

      

    

    
      
        	

              	1.3	
                Eligibility as a Participant is determined by the Company’s Management Board. The President of MorphoSys US, together with the board of directors of MorphoSys US (“Board of Directors”) may propose certain Employees to the Company’s Management Board to become eligible as a Participant.

              

      

    

    § 2

      PLAN VOLUME AND GRANT OF RSUs

    
      
        	

              	2.1	
                Under the RSUP 2020 (US Inc.), up to an aggregate of 127,357 RSUs may
                  be granted. RSUs that are forfeited pursuant to the RSUP Terms & Conditions will once again be available for future grants.

              

      

    

    
      
        	

              	2.2	
                The Company’s Management Board will determine an individual USD award amount (the “Award Amount”) to be granted to a Participant by MorphoSys US by way of a separate award agreement (“Award Agreement”)
                  and such Award Amount will be converted into a certain number of RSUs.

              

      

    

    
      
        	

              	2.3	
                With respect to the conversion of the Award Amount into RSUs, i.e., to calculate the exact number of RSUs to be allocated to a Participant, the respective Award Amount must, in a
                  first step, be converted into a respective amount in Euros (the “Conversion”). The Conversion shall be based on the Euro foreign
                  exchange reference rate, as published on the official website of the European Central Bank (ECB) on the Award Date (as defined in § 2.5) (the “Euro Award Amount”). In a second step, the Euro Award Amount is divided by the average closing price (Schlusskurs) of the Shares
                  on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) in Xetra trading (or a comparable successor system) on the 30 (thirty) trading days
                  prior to the Award Date (as defined in § 2.5) (exclusive), rounded down to the nearest whole number; the number

              

      

    

    
      Page 5/26

      
        

    

    

    

    resulting from such calculation (step one and step two) equals the number of RSUs to be allocated to a Participant (the “Initial Number of RSUs”). If a closing auction does not take place on the relevant trading day(s) or a price is not determined in the auction,
      the applicable price will be the last price quoted in continuous trading, provided there was continuous trading on that trading day.

    For example: If a Participant is granted an Award
      Amount of USD 100,000.00 and the USD/EUR exchange rate on the Award Date is 1 USD = 0.9060 EUR, then the Euro Award Amount amounts to EUR 90,600 (100,000 x 0.9060). If the average closing price (Schlusskurs) of the Shares on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) in Xetra trading on the 30 trading
      days prior to the Award Date amounted to EUR 105.00, then the Initial Number of RSUs to be allocated to the Participant would amount to 862 (EUR 90,600 / EUR 105.00 = 862.85, rounded down to the nearest whole number).

    
      
        	

              	2.4	
                RSUs can be awarded in accordance with legal requirements in each case on 1 April and, in exceptional cases, on 1 October of the respective business year of the Company (the “Award Period”), subject to a continuing and non-terminated (ungekündigt) service relationship or employment of the relevant Participant with MorphoSys US at the relevant Award Date (as defined in § 2.5).

              

      

    

    
      
        	

              	2.5	
                The date on which the Award Agreement becomes effective (the “Award Date”)
                  shall be the date on which the Participant receives the offer to conclude the Award Agreement (irrespective of the point in time the offer to conclude the Award Agreement is accepted), unless the Award Agreement specifies an earlier or a
                  later date as Award Date.

              

      

    

    § 3

      WAITING PERIOD, ANNUAL CYCLE AND VESTING

    
      
        	

              	3.1	
                Each RSU is subject to a waiting period of three (3) years (“Waiting Period”),
                  which shall commence on the day of the Award Date at 00:00 hours (beginning of the day) and end on the day prior to the third anniversary of the Award Date at 24:00 hours (midnight) (“Waiting Period Expiration Date”).

              

      

    

    
      Page 6/26

      
        

    

    

    

    For example: If the Award Date is 1 April 2020, the
      Waiting Period would start on 1 April 2020 at 00:00 hours (beginning of the day) and end on 31 March 2023 at 24:00 hours (midnight).

    
      
        	

              	3.2	
                The Waiting Period is divided into three annual cycles (“Annual Cycles”).
                  The first Annual Cycle will commence on the day of the Award Date at 00:00 hours (beginning of the day) and end on the day prior to the first anniversary of the Award Date at 24:00 hours (midnight), the second Annual Cycle will commence
                  on the day of the first anniversary of the Award Date at 00:00 hours (beginning of the day) and end on the day prior to the second anniversary of the Award Date at 24:00 hours (midnight) and the third Annual Cycle will commence on the day
                  of the second anniversary of the Award Date at 00:00 hours (beginning of the day) and end on the day prior to the third anniversary of the Award Date at 24:00 hours (midnight) (each an “Annual Cycle”).

              

      

    

    
      
        	

              	3.3	
                One third (1/3) of the Initial Number of RSUs will vest at the end of each Annual Cycle subject to the following conditions: (i) the achievement of certain KPIs (§ 4) and (ii) no
                  forfeiture of RSUs pursuant to § 5 (the “Vested RSUs”).

              

      

    

    
      
        	

              	3.4	
                After expiry of the Waiting Period and an administration period in which to determine the settlement amounts, the Company will settle the total number of Vested RSUs; provided,
                  that such settlement shall occur no later than 90 days following the Waiting Period Expiration Date.

              

      

    

    § 4

      KEY PERFORMANCE INDICATORS

    
      
        	

              	4.1	
                With respect to an Annual Cycle, RSUs will vest only if and to the extent the KPIs (as defined in § 4.2) have been reached or exceeded in accordance with the following
                  provisions.

              

      

    

    
      
        	

              	4.2	
                Key Performance Indicators (“KPIs”, and each a “KPI”) are:

              

      

    

    
      
        	

              	4.2.1	
                the EBIT performance of MorphoSys US over the fiscal year in which an Annual Cycle starts, measured and evaluated in relation to the EBIT Performance (as defined in § 4.3) set by
                  the Board of Directors, with the consent of the Company’s Management Board (“EBIT KPI”);

              

      

    

    
      Page 7/26

      
        

    

    

    

    
      
        	

              	4.2.2	
                the revenue performance of MorphoSys US over the fiscal year in which an Annual Cycle starts, measured and evaluated in relation to the Revenue Performance (as defined in § 4.3)
                  set by the Board of Directors, with the consent of the Company’s Management Board (“Revenue KPI”); and

              

      

    

    
      
        	

              	4.2.3	
                the performance of the stock exchange price of the Shares on the Frankfurt Stock Exchange (Frankfurter
                    Wertpapierbörse) in Xetra trading (or a comparable successor system) over the Annual Cycle, measured and evaluated in relation to the Share Price Performance (as defined in § 4.3) set by the Board of Directors, with the consent
                  of the Company’s Management Board (“Share Price KPI”).

              

      

    

    For example: If an Annual Cycle starts on 1 April
      2020, the KPIs will be measured and evaluated on the basis of the EBIT performance and the revenue performance during the fiscal year starting 1 January 2020 through 31 December 2020 and the share price performance will be measured and evaluated on
      the basis of the share price performance during 1 April 2020 until 31 March 2021. If the second Annual Cycle starts on 1 April 2021, the KPIs will be measured and evaluated on the basis of the EBIT performance and the revenue performance during the
      fiscal year starting 1 January 2021 through 31 December 2021 and the share price performance will be measured and evaluated on the basis of the share price performance during 1 April 2021 until 31 March 2022. If the third Annual Cycle starts on
      1 April 2022, the KPIs will be measured and evaluated on the basis of the EBIT performance and the revenue performance during the fiscal year starting 1 January 2022 through 31 December 2022 and the share price performance will be measured and
      evaluated on the basis of the share price performance during 1 April 2022 until 31 March 2023.

    
      
        	

              	4.3	
                The Board of Directors, with the consent of the Company’s Management Board, will determine the performance to be achieved for each KPI with respect to a certain Annual Cycle
                  (respectively the “EBIT Performance”, the “Revenue Performance” and the “Share Price Performance”) and which will, depending on the degree of
                  achievement (as a percentage) of each KPI, correspond with a certain “KPI Achievement Rate” for the respective Annual Cycle,
                  respectively the “EBIT KPI Achievement

              

      

    

    
      Page 8/26

      
        

    

    

    

    Rate”, the “Revenue KPI Achievement Rate”  and the “Share
        Price KPI Achievement Rate” for the respective Annual Cycle. If the KPI Achievement Rate for any of the KPIs exceeds 125.00%, the respective KPI Achievement Rate will nevertheless be 125.00% (“Cap”).

    
      
        	

              	4.4	
                Once the Board of Directors, with the consent of the Company’s Management Board, has determined the KPIs for a certain Annual Cycle pursuant to section 4.3, the Participant will
                  be provided with such information substantially in the form as set out in Exhibit 2 attached hereto.

              

      

    

    
      
        	

              	4.5	
                The “Overall KPI Achievement Rate” for a respective Annual Cycle will
                  be the arithmetic mean (rounded commercially to the nearest whole number) of (i) the EBIT KPI Achievement Rate, (ii) the Revenue KPI Achievement Rate and the (iii) Share Price KPI Achievement Rate, each of which will be determined in
                  accordance with the KPIs that will be provided to a Participant for each Annual Cycle in accordance with § 4.4.

              

      

    

    For example: If the EBIT KPI Achievement Rate for an
      Annual Cycle is 75%, the Revenue KPI Achievement Rate is 35% and the Share Price KPI Achievement Rate is 135%, the Overall KPI Achievement Rate will be calculated as follows:

    Note: In accordance with § 4.3, the Share Price KPI
      Achievement Rate was capped at 125%.

    (75% + 35% + 125%) / 3 = 78.333%, i.e. 78% (rounded commercially to the nearest whole number).

    
      
        	

              	4.6	
                The number of Vested RSUs at the end of an Annual Cycle will be calculated by multiplying (i) one third (1/3) of the Initial Number of RSUs allocated to a Participant with (ii)
                  the Overall KPI Achievement Rate, provided, however, that at least an Overall KPI Achievement Rate of 50.00% must be reached (“Hurdle”),
                  otherwise the number of Vested RSUs for the respective Annual Cycle will be 0.

              

      

    

    The following chart illustrates the number of RSUs that vest at the end of an Annual Cycle pursuant to this § 4, depending on the
      degree of achievement of the Overall KPI Achievement Rate:

    
      Page 9/26

      
        

    

    

    

    	
            Overall KPI Achievement Rate

          	
            Calculation of total number of Vested RSUs for one
              Annual Cycle

          
	
            0%

          	
            Vested RSUs at the end of an Annual Cycle = 0, given that the hurdle of a
              minimum Overall KPI Achievement Rate of at least 50.00% has not been reached

          
	
            1%

          
	
            2%

          
	
            3%

          
	
            [etc.]

          
	
            48%

          
	
            49%

          
	
            < 50.00%

          
	
            50.00% (hurdle)

          	
            [1/3 of Initial Number of RSUs] x 50.00%

          
	
            60%

          	
            [1/3 of Initial Number of RSUs] x 60%

          
	
            70%

          	
            [1/3 of Initial Number of RSUs] x 70%

          
	
            [etc.]

          	
            [etc.]

          
	
            120%

          	
            [1/3 of Initial Number of RSUs] x 120%

          
	
            125%

          	
            [1/3 of Initial Number of RSUs] x 125%

          

    
      
        	

              	4.7	
                After the expiry of the Waiting Period, the Vested RSUs for each Annual Cycle are added to calculate the total number of Vested RSUs.

              

      

    

    For example: If the Initial Number of RSUs granted to
      a Participant was 300 and during the first Annual Cycle an Overall KPI Achievement Rate of 80% was achieved, during the second Annual Cycle an Overall KPI Achievement Rate of 40% was achieved, and during the third Annual Cycle an Overall KPI
      Achievement Rate of 125% (Cap) was achieved, the number of Vested RSUs at the end of the first Annual Cycle is 80 (1/3 of the 300 granted RSUs x 80%), the number of Vested RSUs at the end of the second Annual Cycle is 0 (since the minimum Hurdle of
      50% was not achieved) and the number of Vested RSUs at the end of the third Annual Cycle is 125 RSUs (1/3 of the 300 granted RSUs x 125%). Thus, after expiry of the Waiting Period, the total Vested RSUs that will be settled would be 205 (80 + 0 +
      125).

    § 5

      CONSEQUENCES OF A TERMINATION OF EMPLOYMENT

    
      
        	

              	5.1	
                With respect to an Annual Cycle, RSUs will vest only if the Participant still has an active employment relationship with MorphoSys US at the end of the relevant Annual Cycle.

              

      

    

    
      Page 10/26

      
        

    

    
      
        	

              	5.2	
                If a Participant’s employment at MorphoSys US terminates for any reason (such that the Participant is no longer an Employee) during an Annual Cycle (such Participant a “Leaver”), such Leaver will retain the RSUs that have already vested pursuant to § 3.3 and § 4 with respect to any Annual Cycle
                  completed before the date of the Participant’s effective termination of employment (the “Termination Date”). Any additional RSUs
                  that were granted to such Leaver and that have not vested will not continue to vest following the Termination Date and instead, they shall be forfeited by the Participant on the Termination Date without any compensation or other
                  consideration paid therefor. No partial vesting will take place with respect to any Annual Cycle that is in effect at the time a Termination Date occurs. Any retained RSUs that were vested as of the Participant’s Termination Date shall be
                  paid following the Waiting Period Expiration Date, consistent with § 6, below.

              

      

    

    
      
        	

              	5.3	
                For example: If a Participant is notified of a termination of his employment with MorphoSys US in the
                  example in § 4.7 in the first Annual Cycle, and such termination has a Termination Date that occurs during the second Annual Cycle of the Waiting Period, such Participant will retain the 80 Vested RSUs from the first Annual Cycle;
                  however, the remaining 200 RSUs originally granted to such Participant (applicable to the second and third Annual Cycles) will be forfeited on the Termination Date without compensation or other consideration paid to the Participant. No
                  further vesting of the Participant’s award of RSUs will occur at the end of the second or third Annual Cycles.

              

      

    

    § 6

      CASH PAYMENT CLAIM RESULTING FROM RSUs AND SETTLEMENT OF RSUs

    
      
        	

              	6.1	
                Upon expiration of the Waiting Period, each Vested RSU shall entitle the Participant to a cash payment claim (the “Cash Payment Claim”) against the Company in the amount of the closing price (Schlusskurs) of the
                  Shares on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) in Xetra trading (or a comparable successor system) (i) in case of a Cash
                  Settlement (as defined in § 6.2), on the Cash Settlement Date (as defined in § 6.2) or, (ii) in case of a Share Settlement (as defined in § 6.3), on the day of the resolution of the Company’s Management Board to utilize, with the consent
                  of the Company’s Supervisory Board, the Authorized Capital

              

      

    

    
      Page 11/26

      
        

    

    2019-I against contribution in kind (the “Capital Increase Resolution Date”). If a closing auction does not take place on the relevant trading day(s) or a price is not determined in the auction, the applicable price will be the last price quoted in continuous
      trading, provided there was continuous trading on that trading day.

    
      
        	6.2	
                Within 90 days following the Waiting Period Expiration Date, the Company will settle the Vested RSUs as determined by the Company in its sole discretion by fulfilling the Cash
                  Payment Claim (i) by way of an effective cash payment to a bank account designated to the Company by the respective Participant in advance (the “Cash Settlement”), or (ii) by transferring Shares to the Participant in accordance with § 6.3, or (iii) by a combination of both. In case of a Cash Settlement, the Company will convert the Cash Payment Claim, denominated
                  in Euros, into a USD amount, based on the Euro foreign exchange reference rate, as published on the official website of the European Central Bank (ECB) on the actual date (within 90 days following the Waiting Period Expiration Date) on
                  which such payment is made (the “Cash Settlement Date”).

              

      

    

    
      
        	6.3	
                In the event of a settlement in the form of Shares, whereby Shares are created from a capital increase out of the Authorized Capital 2019-I (Kapitalerhöhung aus Genehmigtem Kapital 2019-I), the respective contribution in kind (Sacheinlage)
                  for the new Shares shall be the Cash Payment Claim (denominated in EUR) resulting from the Vested RSUs. The Cash Payment Claim (denominated in EUR) will then – in the course of the capital increase – be contributed by the Participant to
                  the Company against issuance of one (1) new Share for each one (1) Vested RSU (the “Share Settlement”). In the event of a Share
                  Settlement, the Participant will be required to take all measures necessary to effect the Share Settlement, including, for example, the opening of an account to which the Shares may be booked, the conclusion of a contribution agreement
                  with the Company and/or the subscription of the new Shares to be issued to the Participant by way of a subscription certificate. The actual date (within 90 days following the Waiting Period Expiration Date) on which the new Shares, which
                  were created from the capital increase against contribution in kind, are transferred to the securities’ account of the respective Participant, the “Share Settlement Date”.

              

      

    

    
      Page 12/26

      
        

    

    

    

    For example: If the Waiting Period Expiration Date
      for the 205 Vested RSUs in the example in § 4.7 occurs on 31 March 2023, the Company may decide, in its sole discretion, whether to settle the 205 Vested RSUs by way of a Cash Settlement or a Share Settlement:

    
      
        	

              	(a)	
                In case of a Cash Settlement, the Company will identify the closing price (Schlusskurs)
                  of the Shares on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) in Xetra trading (or a comparable successor system) on the Cash
                  Settlement Date. Assuming, on the Cash Settlement Date, the closing price (Schlusskurs) amounted to EUR 125.00, the Participant’s Cash Payment Claim
                  resulting from the 205 Vested RSUs would amount to EUR 25,625.00. Assuming the EUR/USD exchange rate on the Cash Settlement Date is 1 EUR = 1.1500 USD, the Cash Payment Claim the respective Participant is entitled to would amount to
                  USD 29,468.75.

              

      

    

    
      
        	

              	(b)	
                In case of a Share Settlement, the Company will request certain information from the Participant, which is necessary to perform the Share Settlement. Once the information has
                  been provided by the Participant to the Company, and following the expiry of the Waiting Period, the Company will identify the closing price (Schlusskurs)
                  of the Shares on the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse) in Xetra trading (or a comparable successor system) on the Capital
                  Increase Resolution Date. Assuming, on the Capital Increase Resolution Date, the closing price (Schlusskurs) amounted to EUR 125.00, the
                  Participant’s Cash Payment Claim resulting from the 205 Vested RSUs would amount to EUR 25,625.00. Following such determination, the Company’s Management Board, with the consent of the Supervisory Board, shall resolve to issue 205 new
                  Shares by way of a capital increase in the context of which the Company’s share capital will be increased by EUR 205.00 against contribution in kind of the Cash Payment Claim of the Participant in the aggregate amount of EUR 25,625.00.
                  Following the registration of the consummation of the capital increase, the 205 new Shares will be transferred to a security deposit of the Participant on the Share Settlement Date.

              

      

    

    
      
        	6.4	
                The Company will inform the Participant whether it will make use of the Cash Settlement (as defined in § 6.2) or the Share Settlement (as defined in § 6.3) or a combination of
                  both in advance of the settlement.

              

      

    

    
      Page 13/26

      
        

    

    

    

    § 7

      TRANSFERABILlTY

    
      
        	

              	7.1	
                Neither the RSUs nor the rights of any Participant under any RSU or under the RSUP 2020 (US Inc.) are assignable or otherwise transferable except as provided in this § 7.

              

      

    

    
      
        	

              	7.2	
                The RSUs are transferable only by will or applicable laws of descent upon the death of the relevant Participant.

              

      

    

    § 8

      CHANGE OF CONTROL

    
      
        	

              	8.1	
                For purposes of this § 8, “Change of Control” means the occurrence of
                  any of the following events:

              

      

    

    
      
        	

              	8.1.1	
                if any person or entity becomes the “Beneficial Owner” (as defined in Rule 13d-3 under
                  the Securities Exchange Act of 1934), directly or indirectly, of securities of MorphoSys US representing 50% or more of the total voting power represented by MorphoSys US’s then outstanding voting securities (excluding for this purpose
                  the Company’s or its affiliates or any employee benefit plan of the Company or its affiliates);

              

      

    

    
      
        	

              	8.1.2	
                a merger or consolidation of MorphoSys US, whether or not approved by the Company's Board, other than a merger or consolidation which would result in the voting securities of
                  MorphoSys US outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) more than 50% of the total
                  voting power represented by the voting securities of MorphoSys US or such surviving entity or parent of such corporation outstanding immediately after such merger or consolidation; or

              

      

    

    
      
        	

              	8.1.3	
                the sale or disposition by MorphoSys US of all or substantially all of MorphoSys US’s assets in a transaction requiring stockholder approval.

              

      

    

    
      Page 14/26

      
        

    

    

    

    Notwithstanding anything to the contrary herein, the terms Change of Control shall have a meaning that is consistent with the
      definition of change in control event, change in ownership or change in effective control set forth in Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), but only to the extent that it is necessary to comply with Code Section 409A.

    
      
        	

              	8.2	
                In case a Change of Control occurs during the Waiting Period, § 3.3 shall be amended such that the RSUs shall vest immediately upon the Change of Control, with the calculation of
                  the Overall KPI Achievement Rate to be determined as follows:

              

      

    

    
      
        	

              	8.2.1	
                With respect to Annual Cycles that are already complete at the date when the Change of Control occurs:

              

      

    

    
      
        	

              	(i)	
                if the Overall KPI Achievement Rate exceeds 100% with respect to Annual Cycles that have concluded prior to the Change of Control, then the actual percentage shall apply with
                  respect to the Overall KPI Achievement Rate for such completed Annual Cycles;

              

      

    

    
      
        	

              	(ii)	
                if the Overall KPI Achievement Rate is below 100% with respect to Annual Cycles that have concluded prior to the Change of Control, then the Overall KPI Achievement Rate for such
                  concluded Annual Cycles shall nevertheless be 100%, provided that the Hurdle for such Annual Cycle(s) has been met.

              

      

    

    
      
        	

              	8.2.2	
                With respect to the Annual Cycle during which the Change of Control occurs, as well as for subsequent Annual Cycles that have not yet commenced, as of the date the Change of
                  Control occurs, the Overall KPI Achievement Rate shall be 100% for such Annual Cycle(s), irrespective of the achievement (if any) of the KPIs.

              

      

    

    
      
        	

              	8.3	
                Notwithstanding anything herein to the contrary, all RSUs that vest upon the Change of Control shall be settled only after the Waiting Period has expired and shall be settled in
                  accordance with § 6.

              

      

    

    
      Page 15/26

      
        

    

    

    

    § 9

      ADJUSTMENT IN CASE OF SPECIFIC CAPITAL AND OTHER

      STRUCTURAL MEASURES

    
      
        	

              	9.1	
                In the event of:

              

      

    

    
      
        	

              	9.1.1	
                a capital increase from Company funds by the issue of new shares (Kapitalerhöhung aus
                    Gesellschaftsmitteln);

              

      

    

    
      
        	

              	9.1.2	
                a reduction in the number of Shares by merging Shares without capital reduction (reverse share split) or an increase in the number of Shares without capital increase (share
                  split);

              

      

    

    
      
        	

              	9.1.3	
                a capital reduction (Kapitalherabsetzung) with a change in the total number of Shares
                  issued by the Company; or

              

      

    

    
      
        	

              	9.1.4	
                any other such event having an effect similar to any of the foregoing (each an “Adjustment Event”),

              

      

    

    the Company’s Management Board may – subject to mandatory law – establish financial equality for the Participants to the extent
      necessary to prevent that such Adjustment Event results in a dilution or enlargement of the benefits or potential benefits resulting from the granted RSUs. In such an Adjustment Event the financial equality shall preferably be established by
      adjusting the number of RSUs.

    
      
        	

              	9.2	
                For the avoidance of doubt: No adjustment pursuant to § 9.1 shall occur in the event of:

              

      

    

    
      
        	

              	9.2.1	
                a capital increase from Company funds without the issue of new Shares (Kapitalerhöhung aus
                    Gesellschaftsmitteln ohne Ausgabe neuer Aktien); or

              

      

    

    
      
        	

              	9.2.2	
                a capital reduction without a change in the total number of Shares issued by the Company.

              

      

    

    
      
        	

              	9.3	
                If an adjustment occurs in accordance with this § 9, fractions of shares will not be granted upon the settlement of RSUs nor will they be compensated by a payment in cash.

              

      

    

    
      Page 16/26

      
        

    

    

    

    § 10

      EXTRAORDINARY DEVELOPMENTS

    
      
        	

              	10.1	
                For purposes of this § 10, “Extraordinary Events or Developments”
                  means – subject always to mandatory law – situations where the potential gain realized by the Participant upon the settlement of RSUs (i) is caused by unusual external events and developments; and (ii) cannot be reasonably justified under
                  any circumstances by the development or business perspective of the Company, also taking into account international remuneration and incentive standards. However, the settlement of RSUs by a Participant as such, that results in an
                  economic benefit for the Participant, does not constitute an Extraordinary Event or Development.

              

      

    

    
      
        	

              	10.2	
                In case of Extraordinary Events or Developments, the Company’s Management Board is entitled to adjust in its discretion (pflichtgemäßes Ermessen) the payout in the form of a Cash Settlement or Share Settlement, to the extent required to eliminate such extraordinary effects.

              

      

    

    § 11

      INSIDER TRADING AND BLACK-OUT PERIODS

    
      
        	11.1	
                Any transaction in the Shares granted in case of a Share Settlement (each a “Transaction”)
                  must be conducted in compliance with (i) all applicable insider trading laws and regulations, namely Art. 14, 7 et seqq. MAR, and (ii) all
                  provisions of any insider trading rules established by the Company ((i) and (ii) together the “Insider Trading Rules”). Each
                  Participant is personally responsible for informing himself about, and acting in full compliance with, all applicable Insider Trading Rules. Any individual non-compliance with applicable Insider Trading Rules may lead to the imposition of
                  civil and criminal penalties (as the case may be).

              

      

    

    
      
        	11.2	
                The Company may postpone or delay the settlement of any Vested RSUs by way of a Cash Settlement or Share Settlement or a combination of both to a later point in time due to
                  restrictions under applicable laws and regulations or rejections from competent authorities.

              

      

    

    
      
        	11.3	
                In order to minimize the potential for prohibited insider trading, the Management Board of the Company may establish in its sole discretion

              

      

    

    
      Page 17/26

      
        

    

    periods from time to time during which all or some of the Participants may not engage in transactions involving Shares granted in
      case of a Share Settlement (the “Black-Out Periods”). As a matter of precaution, and notwithstanding any other provisions in these RSUP Terms
      & Conditions, the Participants may not subscribe any new Shares during an applicable Black-Out Period.

    § 12

      LIMITATION OF LIABILITY

    
      
        	

              	12.1	
                The Company (nor any of its management board members, supervisory board members or employees) does not:

              

      

    

    
      
        	

              	12.1.1	
                assume any responsibility or liability for the development of MorphoSys US’s EBIT and/or revenue or for the development of the value or market price of the Company’s Shares;

              

      

    

    
      
        	

              	12.1.2	
                assume any responsibility or liability for the development of the value or market price of the Company’s Shares, including during the Waiting Period and during the period between
                  the Waiting Period Expiration Date and, as the case may be, the Cash Settlement Date, the Capital Increase Resolution Date, or the Share Settlement Date;

              

      

    

    
      
        	

              	12.1.3	
                warrant, assure or guarantee a profit of a Participant from the RSUP 2020 (US Inc.) or any RSU granted thereunder; or

              

      

    

    
      
        	

              	12.1.4	
                warrant, assure or guarantee any increase in value of the RSUs or, following a Share Settlement, the value or market price of the Company’s Shares; in particular it is neither
                  warranted, assured or guaranteed that a Participant will be able to sell his participation in the Company with a profit in the future, nor that no loss will be incurred.

              

      

    

    
      
        	

              	12.2	
                Each Participant declares with his/her participation in the RSUP 2020 (US Inc.) that the participation is voluntary. Each Participant is aware of the fact that he/she alone bears
                  the risk of a decrease in or total loss of value of the RSUs or, following a Share Settlement, the Company’s Shares. Each Participant accepts the offer to participate in the RSUP 2020 (US Inc.) at his/her own risk and assumes any
                  liability relating thereto.

              

      

    

    
      Page 18/26

      
        

    

    

    

    
      
        	

              	12.3	
                Each Participant accepts, that his/her claim stemming from Vested RSUs may be delayed or even forfeited, if he/she does not provide the information requested and required by the
                  Company to perform the Cash Settlement and/or the Share Settlement, in particular, the information in § 6.3.

              

      

    

    
      
        	

              	12.4	
                Each Participant is responsible for obtaining legal, tax and any other necessary advice before participating in the RSUP 2020 (US Inc.) and for evaluating the tax effects
                  connected with the RSUP 2020 (US Inc.). Each Participant accepts and declares that he has not been advised by or on behalf of the Company with respect to his participation in the RSUP 2020 (US Inc.) (in particular, regarding legal and tax
                  issues of such participation).

              

      

    

    § 13

      TAXES, SOCIAL SECURITY AND COSTS

    
      
        	

              	13.1	
                All taxes (including payroll taxes), social security contributions, further duties and costs accrued by the Participant in connection with his/her participation in the RSUP 2020
                  (US Inc.) shall be borne by each Participant. Each Participant is obliged to pay taxes relating to the respective RSUs granted/settled under the RSUP 2020 (US Inc.), or relating to a transfer (if permitted under these RSUP Terms &
                  Conditions) of such RSUs by the Participant to a third party, to the competent tax authorities. Each Participant shall fully indemnify the Company in respect of all such liabilities and obligations against tax authorities.

              

      

    

    
      
        	

              	13.2	
                MorphoSys US is entitled, if required by statutory law, to withhold payroll tax or any other taxes or duties or social security contributions to be paid by (or on behalf and
                  account of) the Participant. This applies even after termination of the service relationship or employment relationship of a Participant with the Company. The Company is entitled to demand the full cooperation of the Participant even
                  after his leave with respect to the

              

      

    

    
      
        	

              	13.3	
                Withholdings mentioned above do not release the Participant from his responsibility and obligation to pay all taxes, social contributions, further

              

      

    

    
      Page 19/26

      
        

    

    

    

    duties and costs being due and accruing in connection with his participation in the RSUP 2020 (US Inc.) or the allocation/grant,
      settlement or transfer of any RSUs.

    
      
        	

              	13.4	
                The compensation and benefits under these RSUP Terms & Conditions are intended to comply with or be exempt from the requirements of Section 409A of the Code, and these RSUP
                  Terms & Conditions will be interpreted and administered in a manner consistent with that intent. The preceding provision, however, shall not be construed as a guarantee by the Company of any particular tax effect to any Participant
                  under these RSUP Terms & Conditions and shall not constitute an indemnity from the Company to any Participant. References to “termination of employment” and similar terms used in these RSUP Terms & Conditions mean, to the extent
                  necessary to comply with Section 409A of the Code, the date that the Participant first incurs a “separation from service” within the meaning of Section 409A of the Code. Each payment under these RSUP Terms & Conditions shall be
                  designated as a “separate payment” within the meaning of Section 409A of the Code.

              

      

    

    

    

    § 14

      FORM REQUIREMENTS

    
      
        	

              	14.1	
                Any legal statements and other notices in connection with the RSUP 2020 (US Inc.) (collectively the “Notices”) or any amendment of these RSUP Terms & Conditions (including an amendment of this § 14.1) shall be made in text form or electronic form (e.g. email) unless any other specific form is required by mandatory law
                  or these RSUP Terms & Conditions.

              

      

    

    Any Notice to be delivered to the Company shall be addressed by email to the Head of Human Resources of
      MorphoSys AG. The Company shall communicate changes in the address set forth in the previous sentence as soon as possible to the Participants. In the absence of such communication, the address stated above shall remain in place.

    
      
        	

              	14.2	
                Any Notice to be given to a Participant may be served by being sent to him/her by email or to his/her home or business address. Each

              

      

    

    
      Page 20/26

      
        

    

    

    

    Participant shall communicate changes of address as soon as possible to the Company.

    § 15

      PROCESSING OF PERSONAL DATA

    The Company processes personal data of the Participants in connection with the administration, implementation and settlement of the
      RSUP 2020 (US Inc.). Additional information regarding the processing of personal data in connection with the RSUP 2020 (US Inc.) is included in Exhibit 1
      (Information on the Processing of Personal Data).

    § 16

      GOVERNING LAW AND JURISDICTION

    
      
        	

              	16.1	
                The RSUP 2020 (US Inc.), any RSUs granted thereunder and these RSUP Terms & Conditions shall be exclusively governed by, and be construed in accordance with, the laws of the
                  Federal Republic of Germany, without regard to principles of conflicts of laws.

              

      

    

    
      
        	

              	16.2	
                Any dispute, controversy or claim arising from or in connection with the RSUP 2020 (US Inc.), any RSUs granted thereunder or these RSUP Terms & Conditions or their validity
                  shall be decided upon by the competent courts in Munich, Germany.

              

      

    

    § 17

      FINAL PROVISIONS

    
      
        	

              	17.1	
                In these RSUP Terms & Conditions, the headings are inserted for convenience only and shall not affect the interpretation of these RSUP Terms & Conditions; where a German
                  term has been inserted in italics, it alone (and not the English term to which it relates) shall be authoritative for the purpose of the interpretation of the relevant English term in these RSUP Terms & Conditions. The terms
                  “including” and “in particular” shall always mean “including, without limitation” and “in particular, without limitation”, respectively. Any reference made in these RSUP Terms & Conditions to any clauses without further indication of
                  a law, an agreement or another document shall mean clauses of these RSUP Terms & Conditions.

              

      

    

    
      Page 21/26

      
        

    

    

    

    
      
        	

              	17.2	
                In the event that one or more provisions of these RSUP Terms & Conditions shall, or shall be deemed to, be invalid or unenforceable, the validity and enforceability of the
                  other provisions of these RSUP Terms & Conditions shall not be affected thereby. In such case, the Company and each Participant agree to recognize and give effect to such valid and enforceable provision or provisions, which correspond
                  as closely as possible with the commercial intent of the Parties. The same shall apply in the event that these RSUP Terms & Conditions contain any unintended gaps (unbeabsichtigte Lücken).

              

      

    

    
      Page 22/26

      
        

    

    

    

    

    

    Planegg, April 2020

    MorphoSys AG

    * * * *

    
      Page 23/26

      
        

    

    

    

    Exhibit 1

    

    

    

    

    Exhibit 1

    

    

    Information on the Processing of Personal Data

      in connection with the Restricted Stock Unit Program 2020

    (hereinafter referred to as “RSUP 2020 (US Inc.)”)

      of MorphoSys AG

    (hereinafter referred to as the “Company”)

    

    

    In connection with the administration, processing and execution of the RSUP 2020 (US Inc.), the Company processes personal data of the beneficiaries
      (hereinafter also referred to as “Data Subjects”) in accordance with the EU General Data Protection Regulation (“GDPR”). Pursuant to the GDPR, the Company is obliged to provide the following information on the processing of personal data. All defined terms used in this
      information have the meaning assigned to them in the option conditions.

    I.          Responsibilities
        and Contact Information

    The controller of the personal data pursuant to Art. 4 para. 7 is the Company:

    

    

    MorphoSys AG

    Semmelweisstraße 7

    82152 Planegg

    Germany

    Telephone:          +49 (0)89 899 27-0

    Facsimile:          +49 (0)89 899 27-222

    E-Mail: info@morphosys.com

    Website: www.morphosys.com

    The Data Protection Officer of the Company can be contacted through:

    MorphoSys AG

    Data Protection Officer

    Semmelweisstraße 7

    82152 Planegg

    Germany

    or

    
      Page 24/26

      
        

    

    Exhibit 1

    

    

    Email: datenschutz@morphosys.com

    II.          Use of Personal
        Data by the Company

    The Company processes personal data of the Data Subjects such as names, contact data, tax numbers and all other information necessary for the
      participation of a Data Subject in the RSUP 2020 (US Inc.) as well as for the administration, processing and execution of the RSUP 2020 (US Inc.) (processing purpose). The legal basis for data processing is Art. 6 Para. 1 (b) GDPR.

    In addition, the Company processes personal data of the Data Subjects if and to the extent required by the law applicable to the Company (e.g., tax
      law). The legal basis for data processing in this respect is Art. 6 para. 1 (c) GDPR.

    III.          Transfer of
        Personal Data

    The Company may disclose personal data to an external service provider (“External Service Provider”) commissioned or involved for the purposes of the administration, processing and/or execution of the RSUP 2020 (US Inc.) in order to support the processing of personal data for the processing purpose set out
      in Section II above. If and to the extent permitted by law, the Company may also commission other third parties to provide certain services, such as IT-services and legal services, for the processing purpose set out in Section II above and may
      disclose personal data to such third parties. These recipients provide their assistance or services to the Company under its control and direction and may have access to personal data to the extent necessary to provide their assistance or services.

    In addition, the Company may, to the extent required and permitted by law, transfer personal data to domestic and foreign authorities or courts in
      order to fulfil legal obligations.

    IV.          Storage and
        Deletion of Personal Data

    The Company processes the personal data within the framework of the participation of the Data Subjects in the RSUP 2020 (US Inc.). The Company deletes
      the personal data if it no longer needs it for the fulfilment of its contractual obligations under the RSUP 2020 (US Inc.) and if there are no legal storage obligations. In the event of a legal obligation to retain personal data, the Company shall
      restrict the processing of such personal data.

    V.          Rights of the
        Data Subjects

    The Data Subjects may, at any time and free of charge, contact the Company or its Data Protection Officer directly with an informal notification in
      order to exercise their

    
      Page 25/26

      
        

    

    Exhibit 1

    

    

    rights under the GDPR. The Data Subjects have the right, subject to the legal requirements, the fulfilment of which is to be examined on a case-by-case
      basis, to request information on their personal data, any rectification or deletion of their personal data, information regarding restrictions on the processing of their personal data and they have the right to receive their personal data in a
      structured, generally used and machine-readable format.

    The Data Subjects also have the right to object to the processing of their personal data, subject to the legal requirements, the fulfilment of which
      must be examined on a case-by-case basis.

    In addition, Data Subjects have the right to lodge a complaint with a supervisory authority.

    

    

    

    

    

    

    

    

  

  Page 26/26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}]]